A315 40 mg and rosuvastatin 5-10 mg (according to UK label). OBJECTIVES: To estimate the cost of treatment for achieving 1 % LDL-C reduction and the cost of getting a patient to LDL-C target of 2 mmol/L with ezetimibe co-administered with simvastatin, compared to atorvastatin and rosuvastatin. METHODS: Following a 6-week run-in period on 40 mg simvastatin, patients were randomized to receive ezetimibe/ simvastatin 10/40 mg, atorvastatin 40 mg or rosuvastatin 5-10 mg for 6 weeks. The total treatment cost for the trial period was estimated. A post-hoc analysis of the trial participants was conducted to compare the treatment cost per patient achieving LDL-C target of 2 mmol/L between the three comparator treatments. The cost of generic simvastatin 40 mg was assumed to be £1.37 for a 28 day treatment (BNF). RESULTS: At the end of the 6 week trial period, the treatment cost per 1% reduction in LDL-C was estimated to be £1.58 (95% CI: £1.42-£1.79) for ezetimibe co-administered with simvastatin. The corresponding treatment costs were £3.33 (£2.64-£4.51) and £9.02 (£4.59-£450.75) for atorvastatin and rosuvastatin, respectively. Cost per patient achieving the LDL-C target of 2 mmol/L was £61.49 (95% CI: £56.66-£67.22) for ezetimibe co-administered with simvastatin compared to £101.84 (£87.69-£121.42) for atorvastatin and £155.06 (£122.54-£211.12) for rosuvastatin. CONCLUSIONS: Co-administration of ezetimibe with simvastatin 40 mg is a cost efficient way of reducing LDL-C compared to atorvastatin 40 mg or rosuvastatin 5-10 mg monotherapy regimen.
1
Pfizer Korea, Seoul, South Korea, 2 Seoul National University College of Pharmacy, Seoul, South Korea, 3 SookMyung Women's University College of Pharmacy, Seoul, South Korea OBJECTIVES: Antihypertensive therapy is a well-established approach to reducing the risk of cardiovascular disease (CVD). The main objective of this meta-analysis was to find out whether the calcium channel blockers are superior, equal, or inferior to other treatments in reducing the frequency of cardiovascular complications. METHODS: Studies were identified through PubMed with a publication date before February 24, 2009. We selected studies in hypertension that assessed cardiovascular events and included at least 100 patients, who were randomly assigned calcium channel blockers or other antihypertensive drugs and who were followed up for at least 1 year. The 2 authors independently assessed studies for inclusion and quality. We extracted from source documents coronary heart disease, stroke, congestive heart failure, cardiovascular disease events, total mortality, cardiovascular disease mortality. RESULTS: The 16 eligible studies included 132,078 patients. Calcium channel blockers provided more protection against stroke than the conventional therapy consisting of diuretics and/or -blockers (risk ratio 0.86, 95% CI 0.80~0.93) and new antihypertensive drugs, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (risk ratio 0.87, 95% CI 0.79~0.96). There were no significant differences in major cardiovascular events risk, total mortality and cardiovascular disease mortality between regimens based on calcium channel blockers and regimens based on the conventional therapy (risk ratio 0.98, 95% CI 0.88~1.09; risk ratio 0.98, 95% CI 0.90~1.06; risk ratio 0.95, 95% CI 0.83~1.07) or new antihypertensive drugs (risk ratio 1.00, 95% CI 0.95~1.05; risk ratio 0.97, 95% CI 0.92~1.02; risk ratio 0.96, 95% CI 0.89~1.04). CONCLUSIONS: These findings suggest that calcium channel blockers decrease the risk of stroke more effectively than other treatments in patients with hypertension. Moreover, when calcium channel blockers were compared with new antihypertensive drugs they demonstrated similar reductions in cardiovascular morbidity and mortality.
PCV20 THE EFFICACY OF CLOPIDOGREL VERSUS THE COMBINATION OF LOW DOSE ASPIRIN PLUS EXTENDED-RELEASE DIPYRIDAMOLE IN PREVENTING SERIOUS VASCULAR EVENTS: A NETWORK META-ANALYSIS
Dewilde S 1 , Eaton J 2 , Hawkins NS 3 1 Services in Health Economics, Brussels, Belgium, 2 Oxford Outcomes (UK), Oxford, Oxfordshire, UK, 3 Oxford Outcomes (UK), Oxford, UK OBJECTIVES: To estimate the relative efficacy of clopidogrel versus low-dose aspirin plus extended-release dipyridamole (ASA ERDP) in preventing serious vascular events among stroke patients. Additionally, to test whether a network meta-analysis (NMA) can give reliable estimates of treatments' relative efficacy in the absence of direct evidence. METHODS: A systematic literature review was conducted in EMBASE and MEDLINE to identify randomized controlled trial (RCT) evidence on the endpoint "serious vascular events" (including myocardial infarction, stroke and vascular death). A NMA with fixed effects was fitted to the data using Winbugs. The NMA was first run on indirect evidence only (NMA_indirect), and these results were compared with results from a NMA including direct and indirect evidence (NMA_all). RESULTS: Three RCTs were identified (ESPS2, ESPRIT, CAPRIE) comparing clopidogrel or ASA ERDP with aspirin; one RCT (PRoFESS) provided direct evidence, two RCTs (CHARISMA and MATCH) provided additional data on clopidogrel through the link with aspirin clopidogrel. Furthermore, one meta-analysis (ATC) compared the efficacy of different aspirin dosages; this was added in the network to link the aspirin arms which differed in dosage. The odds ratio (OR) of ASA ERDP versus clopidogrel for NMA_indirect was 1.15 (0.95:1.37); PRoFESS reported 0.99 (0.92:1.07); and NMA_all resulted in 1.02 (0.95:1.10). All analyses have OR close to "1" and confidence intervals overlapping "1". The point estimate of PRoFESS is within the confidence bounds of NMA_indirect, but the OR from these analyses are in opposite directions. The confidence interval of NMA_all tightens when adding PRoFESS into the network. CONCLUSIONS: The results of the analysis indicate that clopidogrel and ASA ERDP are of equivalent efficacy in preventing secondary serious vascular events. Furthermore, in the absence of direct evidence, statistical techniques such as NMA can provide a reasonable estimate of relative efficacy.
PCV21 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF COMBINATION THERAPIES CONTAINING ARBS VERSUS ACE INHIBITORS
Petrella RJ 1 , Charki M 2 1 Lawson Health Research Institute, London, ON, Canada, 2 sanofi-aventis Group, Paris, France OBJECTIVES: To explore the effectiveness of combination regimens containing Angiotensin Receptor Blockers (ARBs) compared to those containing ACE Inhibitors (ACEIs) in reaching target blood pressure (BP) in a real-world setting. METHODS: Records from a longitudinal population-based database of more than 170,000 patients in over 53 family practice clinics in southwestern Ontario, Canada were analyzed. These records contained chart-abstracted information such as visit diagnosis, BP, medications and consultation notes. The records from adult non-diabetic patients who were diagnosed with hypertension and were initiated on combination therapy in 2005 and continued on the combination for at least 9 months were included. Hypertension was defined as a BP exceeding 140/90 mmHg, chart entry of a diagnosis of hypertension, or use of anti-hypertensive medication. The proportions of patients reaching target BP (BP less than 140/90 mmHg) were recorded. Due to the well known comparable safety profile of the compounds, a safety analysis was not performed. RESULTS: A total of 6160 patients were treated with dual combinations containing an ARB or an ACEI. In patients treated with at least one ARB, 39% reached target BP compared to 31% of those not treated with an ARB (p 0.004). When comparing combinations with HCTZ, 35% and 30% of those on ARB and ACEI, respectively, reached target BP (p 0.006). Within the patients treated with an ARB either in dual or tri-therapy, 48% of patients irbesartan reached target BP when the ARB was irbesartan compared to 42% for losartan or valsartan (p 0.001 for both), and 41% for candesartan (p 0.001). CONCLUSIONS: In a real-world setting, a greater proportion of hypertensive patients treated with a combination containing an ARB reached target BP than those treated with a combination not containing an ARB. Within the ARB class, a greater proportion of patients treated with a combination containing irbesartan reached target BP.
PCV22 CLINICAL EFFICACY OF IMPLANTABLE LOOP RECORDER IN ESTABLISHING THE CAUSES OF UNEXPLAINED OR RECURRENT SYNCOPES
Mrozek M, Wladysiuk M, Kita K, Plisko R, Rys P HTA Consulting, Krakow, Poland OBJECTIVES: The objective of this study was to assess diagnostic efficacy and safety of implantable loop recorder (ILR) in detection of causes of unexplained or/and recurrent syncopes in comparison with conventional diagnostic testing (CDT). METHODS: Comparison was based on a systematic review, carried out according to guidelines published by Medical Services Advisory Committee (MSAC) and the Agency for Health Technology Assessment in Poland. The most important medical databases (MEDLINE, EMBASE, CENTRAL) were searched. Two reviewers independently selected trials, extracted data and assessed their quality (using QUADAS scale). Quantitative analysis was impossible because of heterogeneity between trials with respect to baseline characteristic of participants and meaningful differences in duration of observation periods between ILR and CDT groups. Assessing specificity and sensitivity of ILR was not possible due to lack of reference tests in included studies. Therefore only qualitative analysis was performed. RESULTS: The results of 4 randomized control trial (RCTs) and 32 case series (CSs) were included in the analysis. In 3 RCTs syndromes (syncope and palpitations) were observed in 42-77% of patients in ILR group and 33-73% in CDT group. Determining diagnosis of syncope was successful in 33-73% patients with ILR and in 4-21% patients diagnosed by CDT. The results from 1 RCT indicate that ILR can prevent implantation of pacemaker in 88% patients with unexplained syncope. In CSs syncope and presyncope were reported in 12%-100% patients and ILR enable to obtain diagnosis in 62,5-100% patients. Medical incidents occurred in 2% of patients in CSs. Infections in the insertion site and injuries caused by syncope were most commonly reported. Malfunction of the device occurred in 51 patients in CSs and 1 patient in RCT. CONCLUSIONS: ILR implantation is efficient and safe diagnostic strategy for determine the cause of unexplained or/and recurrent syncope.
PCV23 WHAT IS THE EFFECTIVENESS OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES WHEN USED AS MONOTHERAPY IN THE REAL-WORLD?
Petrella RJ 1 , Massien C 2 1 Lawson Health Research Institute, London, ON, Canada, 2 sanofi-aventis Group, Paris, France OBJECTIVES: This retrospective analysis of a primary care database compares the effectiveness of Angiotensin Receptor Blockers (ARBs) used in monotherapy to ACE Inhibitors (ACEIs), Calcium Channel Blockers (CCBs), Beta-Blockers (BBs) and diuretics in reaching target blood pressure (BP). METHODS: Records from a longitudinal
